Search results
Results From The WOW.Com Content Network
Pazopanib. Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [ 12 ][ 14 ][ 15 ][ 16 ] It is administered by slow ...
Dec 6 (Reuters) - Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with ...
Novartis is the world's first largest in life sciences and agribusiness markets. [6] It is also the second-largest pharmaceutical company by market cap in 2019. [127] Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. [128]
Novartis' experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday. The ...
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
(Reuters) -BeiGene and Swiss drugmaker Novartis have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such ...
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. [ 3 ] [ 4 ] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals , focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.